MedTrace Logo

The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years

NCT04022148 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2800

Last updated 2019-07-19

No results posted yet for this study

Summary

A nonrandomized, non-double blinded prospective cohort study to evaluate the preventive efficacy of quadrivalent HPV6/11/16/18 vaccine for the persistent infection of HPV16 genotype or HPV18 genotype in Japanese women aged 27-45 years.

Conditions

  • Cancer of Cervix
  • Vaccinia

Interventions

BIOLOGICAL

Gardasil

Experimental arm: Vaccine group VS Control arm: Non-Vaccine group

Sponsors & Collaborators

Principal Investigators

  • Tetsuji Kurokawa, A · University of Fukui

Eligibility

Min Age
27 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04022148 on ClinicalTrials.gov